НАСЛЕДСТВЕННЫЕ БОЛЕЗНИ
ТЕРАПИЯ


N

NANOPARTICLES FOR GENE THERAPY
  • CANCER THERAPY
      ◊ targeted gene silencing and cancer therapy by nanoparticle-based delivery systems
  • CARBON-BASED NANOMATERIALS
      ◊ Carbon-based nanomaterials in gene therapy
  • NANOGELS
      ◊ Nanogels: Smart tools to enlarge the therapeutic window of gene therapy
  • SYNTHESIS METHODS
      ◊ Large-Size Plasmids in PLGA Nanoparticles for Gene Editing


    • NEURODEGENERATIVE DISEASE
  • SUBVENTRICULAR ZONE CHANGES
      ◊Therapeutic intervention
  • GENE THERAPY
      ◊ Inducible Expression of GDNF in Transplanted iPSC-Derived Neural Progenitor Cells
      ◊ CRISPR/Cas9 novel treatment of neurodegenerative diseases
      ◊ Gene-based therapies for neurodegenerative diseases
      ◊ CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics
      ◊ In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges
  • THERAPY
      ◊ Modeling Neurodegenerative Diseases with Human Pluripotent Stem Cell-Derived Microglia
      ◊ Postnatal therapeutic approaches in genetic neurodevelopmental disorders
      ◊ Novel therapeutic strategies targeting mitochondria as a gateway in neurodegeneration

    • NEUROTRANSMITTER-RELATED DISORDERS
  • GENE THERAPY
      ◊Gene therapy for neurotransmitter-related disorders
    • NEPHROTIC SYNDROME
  • GENE THERAPY
      ◊New study shows potential of gene therapy in nephrotic syndrome


    • NERVE BREAKING
  • REGENERATION
      ◊Therapeutic approaches


    • NEWCASTLE DISEASE
  • ATTENUATE
      ◊Attenuate Newcastle disease virus by codon modification of the glycoproteins and phosphoprotein genes


    • NON-ALCOHOLIC FATTY LIVER DISEASE
  • THERAPY
      ◊ Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease/a>
    • NON-SMALL CELL LUNG CARCINOMA
  • CHEMOTHERAPY and GENE EDITING
      ◊    Exon skipping induced by CRISPR-directed gene editing regulates the response to chemotherapy in non-small cell lung carcinoma cells
      ◊HSP90: A promising target for NSCLC treatments